<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study</title>
				<funder>
					<orgName type="full">Heffter Research Institute</orgName>
				</funder>
				<funder ref="#_TTQRfez">
					<orgName type="full">Swiss Federal Office for Public Health (BAG</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher>Springer Science and Business Media LLC</publisher>
				<availability status="unknown"><p>Copyright Springer Science and Business Media LLC</p>
				</availability>
				<date type="published" when="2003-11-13">13 November 2003</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Felix</forename><forename type="middle">;</forename><surname>Hasler</surname></persName>
							<email>fehasler@bli.unizh.ch</email>
						</author>
						<author>
							<persName><forename type="first">Ulrike</forename><forename type="middle">;</forename><surname>Grimberg</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marco</forename><forename type="middle">A</forename><surname>Benz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Theo</forename><forename type="middle">;</forename><surname>Huber</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Franz</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Archive University of Zurich University</orgName>
								<address>
									<addrLine>Library Strickhofstrasse 39</addrLine>
									<postCode>CH-8057</postCode>
									<settlement>Zurich</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Zurich Open Repository and Archive</orgName>
								<orgName type="institution">University of Zurich</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">ZORA URL</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Heffter Research Center</orgName>
								<orgName type="institution">Psychiatric University Hospital Zürich</orgName>
								<address>
									<addrLine>Lenggstrasse 31</addrLine>
									<postCode>8029</postCode>
									<settlement>Zürich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Psychopharmacology</title>
						<title level="j" type="abbrev">Psychopharmacology</title>
						<idno type="ISSN">0033-3158</idno>
						<idno type="eISSN">1432-2072</idno>
						<imprint>
							<publisher>Springer Science and Business Media LLC</publisher>
							<biblScope unit="volume">172</biblScope>
							<biblScope unit="issue">2</biblScope>
							<biblScope unit="page" from="145" to="156"/>
							<date type="published" when="2003-11-13">13 November 2003</date>
						</imprint>
					</monogr>
					<idno type="MD5">8D141969BFDD9CE3B095921401B4FC7A</idno>
					<idno type="DOI">10.1007/s00213-003-1640-6</idno>
					<note type="submission">Received: 11 March 2003 / Accepted: 2 September 2003 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2025-04-21T20:04+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Psilocybin</term>
					<term>Dose-effect study</term>
					<term>Psycho(patho)logy</term>
					<term>Neuroendocrinology</term>
					<term>Cardiovascular effects</term>
					<term>Altered states of consciousness</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Rationale: Serotonin (5-Hydroxytryptamine, 5-HT) receptors play an important role in perception, affect regulation and attention.</s><s>Pharmacological challenge with the 5-HT 2A agonist psilocybin (PY) is useful in studying the neurobiological basis of cognition and consciousness.</s><s>Objective: Investigation of dose-dependent effects of PY on psycho(patho)logical and physiological parameters.</s><s>Methods: Eight subjects received placebo (PL), and 45 ("very low dose, VLD"), 115 ("low dose, LD"), 215 ("medium dose, MD"), and 315 ("high dose, HD") mg/kg body weight PY.</s><s>The "Altered States of Consciousness Rating Scale" (5D-ASC), the "Frankfurt Attention Inventory" (FAIR), and the "Adjective Mood Rating Scale" (AMRS) were used to assess the effects of PY on psycho(patho)logical core dimensions, attention, and mood.</s><s>A 24-h electrocardiogram (EKG) was recorded and blood pressure was measured.</s><s>Plasma concentrations of thyroidstimulating hormone (TSH), prolactin (PRL), cortisol (CORT), adrenocorticotropic hormone (ACTH), and standard clinical chemical parameters were determined.</s><s>Results: PY dose dependently increased scores of all 5D-ASC core dimensions.</s><s>Only one subject reacted with transient anxiety to HD PY.</s><s>Compared with PL, MD and HD PY led to a 50% reduction of performance in the FAIR test.</s><s>"General inactivation", "emotional excitability", and "dreaminess" were the only domains of the AMRS showing increased scores following MD and HD PY.</s><s>The mean arterial blood pressure (MAP) was moderately elevated only 60 min following administration of HD PY.</s><s>Neither EKG nor body temperature was affected by any dose of PY.</s><s>TSH, ACTH, and CORT plasma levels were elevated during peak effects of HD PY, whereas PRL plasma levels were increased following MD and HD PY.</s><s>Conclusion: PY affects core dimensions of altered states of consciousness and physiological parameters in a dose-dependent manner.</s><s>Our study provided no cause for concern that PY is hazardous with respect to somatic health.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>The indolealkylamine psilocybin (PY, 4-phosphoryloxy-N,N-dimethyltryptamine) is the main psychoactive principle of hallucinogenic mushrooms such as Psilocybe cubensis and Psilocybe semilanceata.</s><s>PY interacts mainly with serotonergic neurotransmission (5-HT 1A , 5-HT 2A , and 5-HT 2C receptor subtypes).</s><s>Equilibrium dissociation constants (K i ) are 6 nM for the 5-HT 2A receptor subtype and 190 nM for the 5-HT 1A subpopulation <ref type="bibr" target="#b31">(McKenna et al. 1990</ref>).</s><s>PY and its active metabolite psilocin (PI) have-in contrast to lysergic acid diethylamide (LSD)no affinity for dopamine D2 receptors <ref type="bibr" target="#b3">(Creese 1975)</ref>.</s><s>In a receptor-blocking study, we showed that the psychotropic effects of PY could be blocked completely by pretreatment with the 5-HT 2A preferential antagonist ketanserin <ref type="bibr" target="#b48">(Vollenweider et al. 1998)</ref> suggesting that PYinduced effects are mediated primarily via activation of 5-HT 2A receptor subtypes.</s><s>However, some of the psychotropic effects of PY might be due to downstream effects on other neurotransmitter systems.</s><s>For example, we recently demonstrated in a PET study using the D2receptor ligand [ 11 C] raclopride that PY increases striatal dopamine <ref type="bibr" target="#b49">(Vollenweider et al. 1999</ref>).</s><s>The enhanced dopaminergic activity correlated with derealization/depersonalisation phenomena and euphoria.</s><s>Corresponding functional interactions of central dopaminergic and serotonergic systems have been demonstrated <ref type="bibr" target="#b23">(Kapur and Remington 1996)</ref>.</s><s>The pharmacology of PY is reviewed in a paper by <ref type="bibr" target="#b36">Passie et al. (2002)</ref>.</s><s>Aside from the popular (illicit) use as a recreational drug <ref type="bibr" target="#b4">(Cuomo et al. 1994;</ref><ref type="bibr" target="#b28">Lohrer and Albers 1999;</ref><ref type="bibr" target="#b43">Supprian et al. 2001)</ref>, PY can serve as an experimental tool in neurosciences to study the neurobiological basis of altered states of consciousness (ASC) <ref type="bibr" target="#b47">(Vollenweider et al. 1997;</ref><ref type="bibr" target="#b15">Gouzoulis-Mayfrank et al. 1998;</ref><ref type="bibr" target="#b49">Vollenweider et al. 1999;</ref><ref type="bibr" target="#b46">Vollenweider and Geyer 2001)</ref>.</s><s>Recent investigations revealed that the serotonin (5-HT) receptor system is of basic importance also in the modulation of cognitive functions such as memory and attention <ref type="bibr" target="#b33">(Meneses 1998;</ref><ref type="bibr" target="#b2">Buhot et al. 2000;</ref><ref type="bibr" target="#b11">Ellis and Nathan 2001)</ref>.</s><s>Depending on the context, activation or inhibition of 5-HT 2A receptors leads to an improvement or an impairment of working memory function <ref type="bibr" target="#b50">(Williams et al. 2002)</ref>.</s><s>Hence, the 5-HT 2 receptor agonistic mode of action of psilocin (PI, 4hydroxy-N,N,-dimethyltryptamine), the first and pharmacologically active metabolite of PY <ref type="bibr" target="#b17">(Hasler 1997;</ref><ref type="bibr" target="#b27">Lindenblatt et al. 1998</ref>) makes this "classic" hallucinogen also an interesting compound to investigate brain mechanisms underlying attention.</s><s>In view of the diverse and widespread use of PY, its pharmacological and toxicological properties in humans must be closely investigated in order to estimate the safety of PY.</s></p><p><s>Our literature review revealed two human studies on the acute somatic effects of <ref type="bibr">PY from 1959</ref><ref type="bibr" target="#b19">and 1961</ref><ref type="bibr" target="#b21">(Isbell 1959;</ref><ref type="bibr" target="#b19">Hollister 1961</ref>) and one study published in 1999 by <ref type="bibr" target="#b16">Gouzoulis-Mayfrank et al. (Gouzoulis-Mayfrank et al. 1999</ref>) using a single dose of PY in eight subjects.</s><s>Isbell found a clinically irrelevant, although statistically significant, elevation of systolic blood pressure after administration of 86 g/kg body weight PY, but not after 114 g/kg.</s><s>Hollister's clinical-chemical measures of serum cholesterol, alkaline phosphatase, cholinesterase, and aspartatamino-transferase revealed no differences between baseline blood samples and samples taken 2 h post-dose.</s><s>Gouzoulis et al. <ref type="bibr" target="#b16">(Gouzoulis-Mayfrank et al. 1999)</ref> found no significant response of cortisol, prolactin, or growth hormone on administration of a single moderate dose of PY (200 g/kg).</s><s>In the same trial, weak elevations of systolic blood pressure and body temperature were noted.</s><s>In a human study by <ref type="bibr" target="#b42">Strassman and Qualls (1994)</ref>, intravenous N,N-dimethyltryptamine (DMT), a hallucinogenic compound chemically related to PI, dose dependently raised prolactin and cortisol plasma levels.</s></p><p><s>The primary aim of this study was to explore the potential dose-response relationship of PY on multiple levels, encompassing various (neuro-)psychological and physiological parameters.</s><s>The second aim was to estimate the drug safety of PY for further use in human challenge studies and to appraise possible associated risks.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subjects</head><p><s>Eight volunteers (four male and four female; mean age 29.5 years, range 22-44 years) were recruited from university and hospital staff by word of mouth and agreed to participate in the study with written informed consent.</s><s>Subjects were healthy according to physical examination, detailed clinical-chemical blood analysis, and electrocardiogram.</s><s>All subjects were screened by structured psychiatric interview based on the DIA-X computerized diagnostic expert system <ref type="bibr" target="#b51">(Wittchen and Pfister 1997)</ref>.</s><s>Personal and family histories of major psychiatric diseases as well as personal histories of illicit drug use were employed as exclusion criteria.</s><s>The screening procedure was supplemented by standard psychometric instruments (Freiburg Personality Inventory FPI, <ref type="bibr" target="#b12">Fahrenberg et al. 1984;</ref><ref type="bibr">State Trait Anxiety Inventory, Trait form STAI-X2;</ref><ref type="bibr" target="#b26">Laux et al. 1981;</ref><ref type="bibr">and Hopkins Symptom Checklist SCL-90, Derogatis et al. 1973)</ref>.</s><s>Since the personality trait factors "rigidity" and "emotional lability" were identified to be predictors of negative experiences during ASC <ref type="bibr" target="#b6">(Dittrich 1993)</ref>, scores exceeding two SD from the mean value of normative data in the respective subscales of the FPI (i.e., "openness" and "neuroticism") were used as exclusion criteria.</s><s>Apart from sporadic use of cannabis, our subjects had no or very limited experience with psychoactive drugs.</s><s>All subjects were of normal weight (mean body mass index 21.4,</s><s>range 18.5-23.5)</s><s>and all female volunteers had a regular menstrual cycle and did not receive oral contraceptives.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Substances</head><p><s>PY for neurochemical stimulation was obtained through the Swiss Federal Office for Public Health, Department of Pharmaceutics and Narcotics, Bern.</s><s>PY capsules (1 mg and 5 mg) were prepared at the Pharmacy of the Cantonal Hospital of Aarau, Switzerland.</s><s>Quality control comprised tests for identity, purity and uniformity of content.</s><s>PY and lactose placebo were administered in gelatin capsules of identical appearance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>The study protocol was approved by the ethics committee of the University Hospital of Zürich.</s><s>Administration of PY to healthy subjects was authorized by the Swiss Federal Office for Public Health, Department of Pharmaceutics and Narcotics, Bern.</s><s>According to our within-subject study design, each volunteer received placebo (PL) and four different doses of PY in random order on five experimental days at least 2 weeks apart.</s><s>PY dosages were as follows: very low dose (VLD) = 45 g/kg body weight; low dose (LD) = 115 g/kg; medium dose (MD) = 215 g/kg; and high dose (HD) = 315 g/kg.</s><s>Our own investigations <ref type="bibr" target="#b17">(Hasler 1997;</ref><ref type="bibr" target="#b17">Hasler et al. 1997</ref>) revealed that identical doses of PY relative to body weight cause comparable plasma concentration-time profiles of PI.</s><s>We therefore preferred to administer doses relative to body weight rather than absolute amounts of PY.</s><s>Both volunteers and investigators were blind with respect to the experimental condition.</s><s>To minimize confounding effects of circadian rhythms on hormone levels, drug dosing took place at approximately the same time.</s><s>In all female volunteers, the experiments were performed during the early follicular phase of their menstrual cycles.</s><s>Experienced psychiatrists supervised all experiments.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Psychometric scales</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimensions of ASC</head><p><s>The rating scale 5D-ASC <ref type="bibr" target="#b8">(Dittrich 1998;</ref><ref type="bibr" target="#b9">Dittrich et al. 1999</ref>) is a visual-analogue scale suited to depict alterations in waking consciousness-including changes in mood, perception, experience of self and environment, and thought disorders-regardless of the inducing factor(s) <ref type="bibr" target="#b7">(Dittrich 1996</ref><ref type="bibr" target="#b8">(Dittrich , 1998))</ref>.</s><s>Score-sums of the respective items make up the following five dimensions of the 5D-ASC: "oceanic boundlessness" (OB) measures derealization and depersonalization phenomena associated with positive emotional states ranging from heightened mood to euphoria.</s><s>"Anxious ego dissolution" (AED) subsumes dysphoric mood states such as anxiety and fearful delusions, arising mainly from ego-disintegration and loss of self-control phenomena.</s><s>The 5D-ASC main scale "visionary restructuralization" (VR) is constructed of items circumscribing "elementary hallucinations," "synesthesia," "changed meaning of percept," "facilitated recollection," and "facilitated imagination."</s></p><p><s>The "auditory alterations" (AA) scale summarizes acoustic phenomena empirically found during ASC, and the dimension "reduction of vigilance" (RV) depicts states of drowsiness and impairment of alertness and cognitive performance.</s><s>The scale "global ASC score" (G-ASC) is constructed by addition of the scores from the OB, AED and VR subscales.</s><s>Our subjects were asked to complete 5D-ASC rating scales 150 min and 300 min after drug administration and instructed to thereby rate their experience from the intervals 0-150 min and 150-300 min, respectively.</s><s>To facilitate comparison of scales among each other, 5D-ASC data are presented as percentage values indicating percentage of maximum absolute scores.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Affective states</head><p><s>The adjective mood rating scale (AMRS) <ref type="bibr" target="#b22">(Janke and Debus 1978)</ref> represents a multidimensional psychometric test developed for repeated measures of mood states.</s><s>In practice, a list of 60 adjectives depicting mood states (e.g.</s><s>"active," "lost in thought," "sociable") were presented to the subjects 10, 95 and 275 min and 24 h after drug intake.</s><s>The volunteers were instructed to choose from four possible answers ("not at all," "somewhat," "quite," or "strongly" appropriate) to rate gradually to what extent each adjective characterizes their actual mood state.</s><s>The AMRS consists of 15 subscales that can be subsumed interpretatively to seven domains of affective states: performance-related activity (efficiency-activation and concentration), general inactivation (inactivation, tiredness and drowsiness), extroversion-introversion (extroversion plus inverted scores from the introversion scale), general well being (selfconfidence and heightened mood), emotional excitability (excitability, sensitivity and aggressiveness), anxiety-depressiveness (anxiety and depressed mood), and dreaminess.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Frankfurt attention inventory</head><p><s>Dose-dependent effects of PY on sustained attention were assessed 140 min after drug administration using the Frankfurt Attention Inventory (FAIR; <ref type="bibr" target="#b35">Moosbrugger and Oehlschlägel 1996)</ref>.</s><s>This paper and pencil test measuring concentration behavior consists of 640 stimuli with high similarity that have to be discriminated against each other within 6 min.</s><s>The FAIR test quantifies aspects of concentration behavior displayed in four test scores: "marker value" (MV) expresses comprehension of test instructions, "performance value" (PV) informs on the amount of attentively processed test items during a defined test period, "quality value" (QV) depicts the amount of attentively made decisions respective to the total amount of decisions, and the "continuity value" (CV) reflects the extent of continuously upheld concentration over the entire test duration.</s><s>The FAIR task provides good test-retest reliability expressed as a Crohnbachs alpha between 0.85 and 0.91.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Physiological measures</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Electrocardiogram</head><p><s>Electrocardiograms (EKG) were continuously registered for 24 h by use of a portable two-channel Holter recorder, model 90205, supplied by Spacelabs, Burdick.</s><s>EKG monitoring was started 1 h before drug application, and the subjects were instructed to stop the recorder and remove the electrodes the following day.</s><s>Signal quality was monitored with a Cardysuny 501X multichannel electrocardiograph (Fukuda ME, Kogyo, Japan), and data analysis was performed using a medical computer Model 90104A from Spacelabs, Burdick.</s><s>The following EKG standard parameters were examined: mean, minimum and maximum heart rates (min 1 ), number of supraventricular and ventricular extrasystoles (n), maximum S-T elevation (mm and ), maximum S-T depression (mm and ), and number of pauses (asystoles; n).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blood pressure and body temperature</head><p><s>Blood pressure was measured using a Riva-Rocci sphygmanometer (Erka, Switzerland) 30 min before drug intake and at 5, 30, 60, 90, 120, 165 and 210 min.</s><s>The axillary body temperature was recorded at the same time points using a Terumo digital clinical thermometer C2O2.</s></p><p><s>Blood pressure data expressed as mean arterial pressure (MAP) values were calculated as follows: MAP (mm Hg) = diastolic blood pressure + 1/3 (systolic blood pressure diastolic blood pressure).</s><s>Maximum rise of MAP above PL (PL values averaged from 0-210 min post-drug administration) is indicated as D MAX MAP.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blood sampling, blood chemistry, and analysis of hormones</head><p><s>Blood samples for quantification of hormones and clinical-chemical parameters were drawn from an indwelling intravenous catheter into vacutainer tubes 20 min before drug administration and at 105 min and 300 min.</s><s>Plasma was separated by centrifugation (15 min at 3000 rpm) immediately after sampling and stored at 27C until analysis.</s><s>The following blood parameters were later determined at the Institute of Clinical Chemistry of the University Hospital of Zürich: sodium (Na + ), potassium (K + ), chloride (Cl ), urea (UR), creatinine (CR), lactate dehydrogenase (LDH), gamma glutamyltransferase (GGT), alkaline phosphatase (AP), aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), thyroid-stimulating hormone (TSH), prolactin (PRL), cortisol (CORT), and adrenocorticotropic hormone (ACTH).</s><s>Besides sampling into EDTA-containing vacutainer tubes, blood samples for quantification of ACTH were additionally stabilized by adding 2000 KIU of aprotinin <ref type="bibr">(Trasylol)</ref>.</s><s>Analytical methods used for quantification of clinical-chemical parameters and accuracies for the respective assays were as follows: Kinetic JaffØ-reaction (CR; accuracy 1.7% CV) <ref type="bibr" target="#b1">(Bonini et al. 1992)</ref>, enzyme-kinetic assays (LDH; CV 2.9%) <ref type="bibr" target="#b24">(Knedel et al. 1986)</ref>, GGT (CV 0.4%) <ref type="bibr" target="#b1">(Bonini et al. 1992</ref>), ASAT (CV 3.1%) <ref type="bibr" target="#b1">(Bonini et al. 1992)</ref>, ALAT (CV 2.4%) <ref type="bibr" target="#b1">(Bonini et al. 1992)</ref>, and AP (CV 2.5%) <ref type="bibr" target="#b24">(Knedel et al. 1986</ref>), ion-selective potentiometric assays (Na + ; CV 0.5%), K + (CV 1.0%) and Cl (CV 0.8%) <ref type="bibr" target="#b1">(Bonini et al. 1992)</ref>, electro-chemiluminescence technology (TSH; CV 3.9%) and CORT (CV 2.8%), chemiluminescence immunometric methods (ACTH; CV 8.8%) and PRL (CV 9.6%) <ref type="bibr" target="#b39">(Robinson and Nelson 1983)</ref>, and urease-GLDH assay (UR; CV 2.6%) <ref type="bibr" target="#b1">(Bonini et al. 1992)</ref>.</s><s>Additional standard hematology analysis, including automated complete blood counts, was performed prior to the first and at the end of the last experimental day.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>All statistical calculations were performed using the STATISTICA for windows software, version 6.0.</s><s>According to the within-subject design of the study, every subject served as her/his own control in order to minimize effects of intraindividual variation in physiological and psychological test scores.</s><s>Univariate two-way ANOVAs with treatment (PL and four doses of PY) and observation time as repeated measures were used to reveal differences between PL and drug conditions for all parameters.</s><s>When significant main effects or interactions were detected with the ANOVA procedure, post-hoc pair-wise comparisons were performed using the Tukey HSD tests.</s><s>Significance levels of main effects are cited in the text.</s><s>Probability values of P&lt;0.05 were considered statistically significant.</s></p><p><s>Trapezoid calculation of AUC values ("Area under the datatime curve") for analysis of blood pressure and body temperature data was performed in Microsoft Excel 2000, using the equation</s></p><formula xml:id="formula_0">AUC 0Àt ðÞ ¼ X nÀ1 i¼0 t iþ1 À t i 2 MAP i þ MAP iþ1 ðÞ :</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acute psychological effects of psilocybin</head><p><s>First subjective changes were perceived by the volunteers usually 20-40 min following administration of PY.</s><s>Peak effects were reported after 60-90 min, lasting for another 60-120 min.</s><s>PY effects then gradually subsided and were completely worn off at the 6-h point.</s><s>Already, the threshold dose of 45 g/kg PY (VLD) was rated clearly psychoactive by most of our volunteers.</s><s>Slight drowsiness and increased sensitivity and intensification of preexisting mood states were most prominent effects at this dosage level.</s><s>LD, MD and HD PY (115, 215 and 315 g/ kg) dose dependently induced changes in mood states, sensory perception (including colorful visual illusions, complex scenic hallucinations and synesthesias), as well as alterations in perception of time, space, and self.</s><s>Typically, the experiences after MD and HD PY were rated positive, with retrospective statements ranging from "pleasurable" to "ineffably beautiful."</s><s>"Magic" or "phantasmagoric" were terms often used to circumscribe a PY experience.</s><s>However, one volunteer (male, 23 years) reacted with pronounced anxiety to HD PY.</s><s>He reported a fearful experience marked by depressed mood and fear of losing control.</s><s>Without pharmacological intervention, his anxiety during the plateau phase of PY action gradually subsided and the dysphoric reaction was completely resolved six hours post-drug ingestion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimensions of ASC</head><p><s>Figure <ref type="figure">1</ref> shows detailed psychometric data from the 5D-ASC rating scale regarding four doses of PY compared with PL condition.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acute physiological effects of psilocybin</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Electrocardiogram</head><p><s>ANOVA calculations revealed no differences in any of the examined parameters of the Holter-24 h EKG.</s><s>No evidence for a PY-induced change of cardiac electrophysiology was found.</s><s>In Table <ref type="table" target="#tab_3">3</ref>, all EKG results and F and P values from the respective statistical calculations are resumed.</s><s>In order to compactly display the EKG results, all data were classed in three intervals: the baseline interval ("interval 1"; t 01 h -t 0 ), the interval of acute effects of PY ("interval 2"; t 0 -t 0+6 h ), and the interval covering the time from the end of subjective drug action up to 24 h ("interval 3"; t 0+6 h -t 0+24 h ).</s><s>Fig. <ref type="figure" target="#fig_0">2a</ref>, and systolic and diastolic blood pressure following HD PY and PL are depicted in Fig. <ref type="figure" target="#fig_0">2b</ref>.</s><s>Axillary body temperature was not significantly influenced by any of the applied doses of PY (F 4,28 =0.94, P=0.452).</s><s>ANOVA of the corresponding area under the data-time curves also did not reveal statistical differences between the groups.</s><s>Effects of PY on blood pressure and body temperature are summarized in Table <ref type="table" target="#tab_4">4</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuroendocrine data</head><p><s>ANOVA of the hormone plasma concentrations revealed a statistically significant main effect of drug only for PRL (F 4,28 =6.41, P=0.0009), whereas significant dose time interactions were found for all monitored hormones (TSH: F 8,56 =3.95, P=0.0009; PRL: F 8,56 =4.68, P= 0.0002; ACTH: F 8,56 =4.23, P=0.0005; and CORT: F 8,56 =2.43, P=0.025).</s><s>Tukey HSD post-hoc pairwise comparison with corresponding values after PL treatment revealed significantly elevated plasma levels for all measured parameters in blood samples collected 105 min following HD PY (TSH following PY 315 g/ kg, P&lt;0.01; PRL following PY 315 g/kg, P&lt;0.001; ACTH following PY 315 g/kg, P&lt;0.01; and CORT following PY 315 g/kg, P&lt;0.05).</s><s>PRL plasma concentrations were already increased following MD PY (PRL following PY 215 g/kg, P&lt;0.01).</s><s>In the plasma samples collected 300 min post-drug administration, all hormone concentrations were back to pre-dose levels.</s><s>Detailed data for time-and dose-dependent effects of PY on plasma levels of hormones are given in Table <ref type="table" target="#tab_5">5</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Blood chemistry and hemogram</head><p><s>With the exception of two liver enzymes determined in plasma samples taken 105 min following administration of HD PY (ASAT and GGT; see beneath), PY did not elicit statistically significant responses from any of the analyzed clinical-chemical blood parameters.</s><s>Mean plasma concentrations of all monitored compounds as well as F and P values deriving from ANOVA calculations of main effects of drug are summarized in Table <ref type="table" target="#tab_6">6</ref>.</s><s>Statistically significant drug time interactions were found  Comparison of hemograms from blood samples preceding the first and following the last experimental day revealed no differences whatsoever in any parameter.</s><s>None of the hematological parameters of any subject was out of normal range.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Acute psychological effects of psilocybin Psilocybin (PY) dose dependently induced important alterations of perception, affect, ego-functions, and attention in all subjects.</s><s>The phenomenological concept of ego-functions (e.g., ego-identity, ego-vitality, egodemarcation, etc.) and their perturbations in the course of ASC or psychopathology is explained by <ref type="bibr" target="#b40">Scharfetter (1981)</ref>.</s><s>Analysis of the 5D-ASC scores revealed that only MD and HD PY led to a relevant loosening of egoboundaries (OB/AED) and to pronounced changes of perception (VR).</s><s>The loosening of the demarcation between self and environment was generally accompanied by insight and experienced as "touching" or "unifying with a higher reality" (OB).</s><s>In one subject, however, HD PY transiently led to a disturbance of ego functions that was experienced with pronounced anxiety (AED).</s><s>Also, only MD and HD PY induced intermittent geometric and complex visual hallucinations, whereas VLD and LD PY led to illusions in terms of intensification or distortion of visual perception (VR).</s><s>PY also amplified or altered acoustic perception (AA), but no auditory hallucinations occurred during any of the experiments.</s><s>All PY-induced symptoms were worn off completely 6-8 h after drug administration.</s></p><p><s>As expressed in scores from the AMRS mood rating scale, increased general inactivation, introversion, and dreaminess were seen robustly in all subjects.</s><s>A statistically significant increase in the AMRS subscale "dreaminess" was still present in the rating 24 h following administration of HD PY, presumably representing the need to reflect and integrate the content of a profound hallucinogen experience well into the next day.</s><s>Administration of both VLD and LD PY induced a mental condition described by one volunteer as "switching between the worlds".</s><s>In this state, normal waking consciousness is intermittently pervaded with transient and unstable drug states in a wavelike pattern, but the "insightfulness" typically experienced after higher doses of PY is absent.</s><s>When distinct hallucinogenic effects were perceived following the two lower doses, they were short lasting and only present for about 1-2 h.</s><s>The effecttime course following VLD PY supports our previous findings <ref type="bibr" target="#b17">(Hasler 1997;</ref><ref type="bibr" target="#b18">Hasler et al. 1997)</ref>, that PY effects arise and wear off with a certain blood level of PI (approximately 4-6 ng PI/ ml plasma).</s><s>This opposes the alternative hypothesis that PY might initiate secondary downstream brain mechanisms whose subjective effects could well outlast the presence of pharmacologically relevant amounts of the active compound in the bloodstream.</s><s>We abstained from monitoring plasma concentration-time profiles of PI, since reliable determination of this highly unstable phenolic compound requires a sophisticated and costly analysis technique <ref type="bibr" target="#b18">(Hasler et al. 1997;</ref><ref type="bibr" target="#b27">Lindenblatt et al. 1998)</ref>.</s></p><p><s>Interestingly, several subjects could not clearly state in retrospect on which experimental day they had received VLD and LD PY, or MD and HD PY, respectively.</s><s>The fact that VLD and LD PY as well as MD and HD PY have common "qualities" in respect of subjective effects is also mirrored in the results from the FAIR attention test.</s><s>Individual scores for the "performance value" and "continuity value" were almost identical following VLD and LD PY, and MD and HD PY, respectively.</s><s>Following MD and HD PY, both FAIR scores were reduced to roughly 50% of the scores reached after PL, VLD, or LD PY.</s><s>The strongly impaired performance in the FAIR test under MD and HD PY is difficult to appraise, since the obvious reduction of attentional abilities due to 5-HT 2A receptor overstimulation may well be confounded by the (also drug-induced) lack of motivation to perform well in this task, as stated by several subjects.</s></p><p><s>Scores from the 5D-ASC dimension RV indicate that vigilance is reduced less following HD PY than after MD PY.</s><s>We propose that following PY in a dosage of 315 g/ kg body weight, noradrenergic neurotransmission is significantly stimulated as well, leading to an overcompensation of the more inactivating effects of predominantly 5-HT stimulation induced by lower PY doses.</s><s>This reasoning is in line with the hypothesis that hallucinogeninduced inhibition of Raphe neurons leads to an increased activity of adjacent noradrenergic neurons of the locus coeruleus <ref type="bibr" target="#b30">(Marek and Aghajanian 1998;</ref><ref type="bibr" target="#b0">Aghajanian and Marek 1999)</ref>.</s><s>As shown in Table <ref type="table" target="#tab_5">5</ref>, administration of PY led to an increase of plasma concentrations of all analyzed hormones (TSH, PRL, ACTH, and CORT) in samples collected 105 min following drug administration, i.e., during peak effects of PY.</s><s>PY-induced changes in plasma levels of TSH, PRL, ACTH and CORT have not been previously reported.</s><s>By the 300-min point, all endocrine parameters were back to baseline values.</s><s>Due to a pronounced variability in plasma levels, statistically significant differences in plasma concentrations relative to the PL condition were reached for all hormones only following HD PY, and for PRL also following MD PY.</s><s>It is noteworthy that only PRL levels in plasma samples taken 105 min post-HD PY (28.0€7.5) were out of the normal physiological range (3.4-24.1 g/l).</s><s>Taking into account that CORT plasma levels follow a circadian rhythm, it is difficult to distinguish between drug effect and physiological daily fluctuations.</s><s>The effect of circadian endocrine fluctuation was controlled to some degree by starting the experiments at the same time each day.</s><s>It is unlikely that increased ACTH and CORT plasma concentrations following HD PY are an expression of stress, because no correlation between CORT levels and scores of the anxiety depicting 5D-ASC subscale AED (r=0.035) were found.</s><s>An increase of ACTH and CORT plasma concentrations as a direct result of 5-HT 2 receptor stimulation is not surprising, because both animal and human studies suggest that pharmacological stimulation of 5-HT mechanisms activates the hypothalamo-pituitaryadrenal (HPA) axis, resulting in a release of ACTH and corticosteroids into the blood stream <ref type="bibr" target="#b14">(Fuller 1981;</ref><ref type="bibr" target="#b20">Holmes et al. 1982;</ref><ref type="bibr" target="#b45">Van de Kar et al. 2001)</ref>.</s><s>Following 5-HT 2 receptor stimulation, hypothalamic neurosecretory transducer cells liberate corticotropin releasing hormone (CRH), leading to an increase of ACTH and CORT plasma concentrations.</s><s>Our findings are in line with the results of a study by <ref type="bibr" target="#b16">Gouzoulis-Mayfrank et al. (1999)</ref> comparing psychological and physiological effects of single moderate doses of d-amphetamine, 3,4-methylenedioxyethylamphetamine (MDE) and PY.</s><s>In their investigation, administration of approximately 200 g/kg PY also led to a statistically non-significant increase of CORT plasma concentrations.</s><s>In contrast, their administration of MDE induced a robust increase of CORT plasma concentrations in all volunteers.</s><s>These findings suggest that acute stimulation of 5-HT release (as it is caused by MDE), is more important for activation of the HPA-axis than direct agonistic action at the 5-HT 2 receptor.</s></p><p><s>PY-induced increase in 5-HT activity is also reflected by an elevation of PRL plasma levels following administration of MD and HD PY.</s><s>This finding was not unexpected, because release of PRL from the anterior pituitary is controlled by inhibitory tuberoinfundibular dopaminergic neurons and by stimulatory 5-HT mechanisms <ref type="bibr" target="#b37">(Prescott et al. 1984;</ref><ref type="bibr" target="#b44">Van de Kar et al. 1985)</ref>.</s><s>That is, dorsal raphe nucleus 5-HT neurons that project to the hypothalamus appear to be involved in the secretion of PRL <ref type="bibr" target="#b32">(Meltzer and Nash 1988)</ref>.</s></p><p><s>The finding of a moderate, but statistically significant increase of TSH plasma levels following administration of HD PY is difficult to interpret, because functional relationships between the hypothalamic-pituitary-thyroid (HPT) axis and 5-HT mechanisms are not well understood and still controversially discussed <ref type="bibr" target="#b25">(Krulich 1982;</ref><ref type="bibr" target="#b29">Mannisto 1983;</ref><ref type="bibr" target="#b10">Duval et al. 1999)</ref>.</s><s>Some experimental findings from animal studies indicate that the central 5-HT system has an inhibitory influence on TSH secretion <ref type="bibr" target="#b34">(Mitsuma and Nogimori 1983)</ref>, whereas others propose the absence of a significant role for 5-HT in the physiological release of TSH <ref type="bibr" target="#b35">(O'Malley et al. 1984</ref>).</s><s>Yet other researchers suggest that 5-HT increases TSH release into the bloodstream, probably by increasing TRH (thyroid-releasing hormone) production or by facilitating the pituitary TSH response to TRH <ref type="bibr" target="#b41">(Silva and Nunes 1996)</ref>.</s><s>Our finding of elevated TSH blood levels following 5-HT 2 receptor challenge is consistent with the hypothesis of stimulation of the HPT axis by 5-HT mechanisms.</s><s>Neuroendocrinological research studies using pre-treatment with selective 5-HT receptor agonists and antagonists might contribute to a better understanding of this issue.</s></p><p><s>Statistical analysis of plasma concentrations of a multitude of clinical chemical markers (Table <ref type="table" target="#tab_6">6</ref>) revealed that PY has an effect solely on two liver enzymes: ASAT and GGT.</s><s>Thereby, only HD PY led to a statistically significant, although clinically irrelevant, short-term increase of these enzymes.</s><s>It is noteworthy that also the transiently increased ASAT and GGT plasma concentrations were not out of normal physiological ranges [ASAT: 10-31 U/l (female) and 10-34 U/l (male); GGT: 7-32 U/l (female) and 11-50 U/l (male)].</s><s>In blood samples taken 300 min following HD PY, ASAT and GGT values were back to pre-dose levels and no longer significantly different from respective concentrations determined under the PL condition.</s><s>We interpret the finding of a transient elevation of ASAT and GGT following HD PY as a sign of non-specific increase of liver enzyme activity as it is often seen in "liver sensitive" subjects following administration of a multitude of drugs <ref type="bibr" target="#b13">(Fried 2000)</ref>.</s></p><p><s>We see two methodological limitations for the present study.</s><s>First, the moderate number of eight subjects may lead to some distortion of the results, whereby a putative bias is expected to be most pronounced for psychological variables.</s><s>Parameters with small effect sizes are unlikely to reach the level of statistical significance and therefore minor effects, e.g., following lower doses of PY, could have been missed.</s><s>Second, one might argue that the highest dose of PY (315 mg/kg) used in this study is not a "real" high dose, and some effects of PY would be clearly apparent only following higher doses of PY.</s><s>To the best of our knowledge, no controlled clinical studies in humans have been conducted using higher doses of PY.</s><s>For safety reasons, we decided to not use more PY because we were not willing to expose our subjects to a potentially more stressful drug effect at this early stage of investigations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Our investigations provided no cause for concern that administration of PY to healthy subjects is hazardous with respect to somatic health.</s><s>However, as our data revealed tendencies of PY to temporarily increase blood pressure, we advise subjects suffering from cardiovascular conditions, especially untreated hypertension, to abstain from using PY or PY-containing mushrooms.</s><s>Furthermore, our results indicate that PY-induced ASC are generally well tolerated and integrated by healthy subjects.</s><s>However, a controlled clinical setting is needful, since also mentally stable personalities may, following ingestion of higher doses of PY, transiently experience anxiety as a consequence of loosening of ego-boundaries.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 2 a</head><label>2</label><figDesc><div><p><s>Fig. 2 a Average mean arterial blood pressure (MAP) following four doses of psilocybin and placebo, respectively (n=8).</s><s>b Systolic and diastolic blood pressures following administration of placebo and HD psilocybin (mean€SEM, n=8)</s></p></div></figDesc><graphic coords="8,48.19,50.83,243.82,406.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="5,48.19,416.50,498.84,269.92" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc><div><p><s>Subjective effects of psilocybin.Dose-dependent scores in the seven domains of affective states from the adjective mood rating scale (AMRS)(mean€SEM, n=8)</s></p></div></figDesc><table><row><cell></cell><cell>Placebo</cell><cell>Psilocybin VLD (45 g/kg)</cell><cell>Psilocybin LD (115 g/kg)</cell><cell>Psilocybin MD (215 g/kg)</cell><cell>Psilocybin HD (315 g/kg)</cell></row><row><cell>Rating 1 (baseline)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Performance-related activity General inactivation Extroversion-introversion General well being Emotional excitability Anxiety-depressiveness Dreaminess</cell><cell>19.1€1.4 16.5€1.6 4.4€1.1 20.0€1.7 15.4€0.7 8.3€0.2 6.3€0.8</cell><cell>19.3€1.0 15.0€2.2 4.6€0.9 20.3€1.2 15.3€0.7 9.0€0.8 6.4€0.7</cell><cell>18.9€1.7 16.3€2.3 5.1€1.1 22.6€1.4 15.6€1.1 8.0€0.0 5.9€0.6</cell><cell>17.4€0.7 13.9€1.0 3.5€0.6 19.5€1.9 16.5€1.0 9.0€0.6 6.0€0.5</cell><cell>16.6€1.4 17.6€2.6 3.0€0.9 18.6€2.2 16.7€1.7 9.9€1.1 5.9€0.7</cell></row><row><cell>Rating 2 (t 0+95 min )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Performance-related activity General inactivation Extroversion-introversion General well being Emotional excitability Anxiety-depressiveness Dreaminess</cell><cell>17.8€1.2 14.6€1.8 5.3€0.7 18.6€1.9 14.9€1.3 9.0€0.7 6.4€0.7</cell><cell>16.4€0.9 18.0€2.5 2.8€1.4 20.4€1.5 15.0€0.9 8.6€0.5 7.3€0.9</cell><cell>15.1€1.4 21.0€2.2 1.9€1.2 20.9€1.8 15.0€0.9 8.7€0.4 7.6€0.7</cell><cell>14.9€1.2 23.5€1.9*** 0.3€1.7** 22.4€2.0 17.8€1.7 8.9€0.4 11.6€1.0***</cell><cell>14.9€1.7 24.9€2.0*** 1.9€1.4*** 22.0€2.5 20.6€2.2*** 11.6€2.6 10.6€0.8***</cell></row><row><cell>Rating 3 (t 0+275 min )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Performance-related activity General inactivation Extroversion-introversion General well being Emotional excitability Anxiety-depressiveness Dreaminess</cell><cell>18.3€1.3 13.6€0.7 4.8€1.0 19.6€1.9 14.6€0.9 8.3€0.3 6.0€0.7</cell><cell>17.8€1.2 16.0€2.1 4.6€0.9 20.1€1.5 14.9€1.6 8.5€0.5 6.4€0.9</cell><cell>16.3€1.0 17.0€1.5 2.7€1.1 21.1€1.6 15.1€1.1 8.6€0.4 6.7€0.8</cell><cell>16.6€0.8 17.0€1.7 2.0€1.4 21.1€1.3 15.5€1.2 8.4€0.4 7.3€0.9</cell><cell>16.0€0.9 21.6€2.3** 1.6€1.6 22.6€1.3 15.7€1.2 8.7€0.5 10.6€0.5***</cell></row><row><cell>Rating 4 (t 0+24 h )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Performance-related activity General inactivation Extroversion-introversion General well being Emotional excitability Anxiety-depressiveness Dreaminess</cell><cell>19.7€1.1 14.0€0.7 5.4€1.0 19.7€1.7 15.9€1.1 9.4€0.7 5.1€0.5</cell><cell>20.0€1.3 14.3€0.9 5.3€0.6 19.8€1.3 14.8€1.3 8.4€0.4 5.1€0.5</cell><cell>20.6€1.2 14.7€0.9 5.3€0.3 21.0€0.9 15.4€0.9 8.9€0.5 5.6€0.7</cell><cell>18.7€1.1 18.4€2.0 3.0€1.1 18.7€1.0 15.3€1.5 9.3€0.7 7.3€1.0</cell><cell>16.3€1.3 18.7€1.4 1.4€1.8 17.9€1.3 16.4€0.9 10.6€1.1 8.4€0.8**</cell></row></table><note><p><s>averaged PL values (D MAX MAP; F 3,21 =1.04, P=0.396), and area under the MAP-time curve (AUC (0-t) MAP; F 4,28 =2.43, P=0.071) was found.ANOVA analysis, however, detected a significant dose time interaction(F 28,196=2.34,P=0.0004).As depicted in Fig.2a, b, a PY, relative to PL (P&lt;0.001).</s><s>Diastolic blood pressure was significantly elevated (P&lt;0.05)</s><s>only 90 min following intake of HD PY.</s><s>Time courses of averaged MAP values following four doses of PY and PL are shown in</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc><div><p><s>Effects of psilocybin on sustained attention.Scores from the Frankfurt attention inventory(FAIR; mean€SEM, n=8)</s></p></div></figDesc><table><row><cell></cell><cell>Placebo</cell><cell>Psilocybin VLD (45 g/kg)</cell><cell>Psilocybin LD (115 g/kg)</cell><cell>Psilocybin MD (215 g/kg)</cell><cell>Psilocybin HD (315 g/kg)</cell></row><row><cell cols="2">Rating at 140 min post-drug ingestion</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Marker value (MV) Performance value (PV) Quality value (QV) Continuity value (CV)</cell><cell>0.991€0.003 480.6€33.4 0.943€0.014 455.9€34.4</cell><cell>0.991€0.003 456.5€25.8 0.959€0.014 438.9€28.0</cell><cell>0.993€0.003 455.8€31.9 0.961€0.004 439.4€32.3</cell><cell>0.984€0.009 260.7€25.0 *** 0.927€0.029 242.6€27.0 ***</cell><cell>0.987€0.002 258.0€42.0 *** 0.910€0.025 243.6€43.3 ***</cell></row><row><cell cols="3">*P&lt;0.05 **P&lt;0.01 ***P&lt;0.001 compared with placebo condition (Tukey HSD post-hoc test)</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3</head><label>3</label><figDesc><div><p><s>Electrocardiographic data following placebo and four doses of psilocybin(mean€SEM, n=8)</s></p></div></figDesc><table><row><cell>Placebo</cell><cell>Psilocybin VLD (45 g/kg)</cell><cell>Psilocybin LD (115 g/kg)</cell><cell>Psilocybin MD (215 g/kg)</cell><cell>Psilocybin HD (315 g/kg)</cell><cell>Main effect of drug F (4, 28) values</cell><cell>Main effect of drug P values</cell></row><row><cell>Interval 1 (baseline; t 01 h -t 0 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean heart rate (min 1 ) Minimum heart rate (min 1 ) Maximum heart rate (min 1 ) Supraventricular extrasystoles (n) Ventricular extrasystoles (n) Maximum S-T elevation (mm) Maximum S-T elevation (slope, ) 27€7 78€5 57€4 126€6 1€1 2€1 1.3€0.4 Maximum S-T depression (mm) 0.3€0.2 Maximum S-T depression (slope, ) 10€4 Pauses (n) 0€0</cell><cell>79€5 62€3 120€6 1€1 1€1 2.0€0.4 45€8 0.1€0.2 17€6 0€0</cell><cell>75€3 58€3 130€5 1€1 2€2 2.5€0.5 46€5 0.3€0.3 18€6 0€0</cell><cell>85€6 60€4 130€7 1€1 1€1 1.6€0.3 46€4 0.2€0.5 18€5 0€0</cell><cell>82€6 65€4 112€7 1€1 1€1 1.6€0.2 37€6 0.0€0.2 14€4 0€0</cell><cell>0.601 0.589 2.280 2.058 2.492 1.570 1.230 0.918 1.178 0.148</cell><cell>0.665 0.673 0.086 0.114 0.067 0.210 0.321 0.467 0.341 0.963</cell></row><row><cell>Interval 2 (t 0 -t 0+6 h )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean heart rate (min 1 ) Minimum heart rate (min 1 ) Maximum heart rate (min 1 ) Supraventricular extrasystoles (n) Ventricular extrasystoles (n) Maximum S-T elevation (mm) Maximum S-T elevation (slope, ) 35€8 85€5 60€4 141€5 21€6 16€7 1.5€0.4 Maximum S-T depression (mm) 0.0€0.2 Maximum S-T depression (slope, ) 8€4 Pauses (n) 0€0</cell><cell>82€5 62€4 128€6 7€3 2€2 2.2€0.6 46€8 0.4€0.3 16€6 0€0</cell><cell>82€5 61€2 137€8 19€9 5€4 2.6€0.5 49€5 0.4€0.3 14€8 0€0</cell><cell>87€6 60€3 140€8 5€2 5€3 1.9€0.3 50€4 0.4€0.3 20€6 0€0</cell><cell>84€4 63€2 131€6 4€3 3€2 1.6€0.3 43€7 0.2€0.1 13€4 0€0</cell><cell></cell><cell></cell></row><row><cell>Interval 3 (t 0+6 h -t 0+24 h )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean heart rate (min 1 ) Minimum heart rate (min 1 ) Maximum heart rate (min -1 ) Supraventricular extrasystoles (n) Ventricular extrasystoles (n) Maximum S-T elevation (mm) Maximum S-T elevation (slope, ) 25€6 73€3 55€3 121€2 9€3 8€3 1.1€0.3 Maximum S-T depression (mm) 0.2€0.2 Maximum S-T depression (slope, ) 10€4 Pauses (n) 1€1</cell><cell>74€5 60€4 115€6 11€5 6€3 2.1€0.6 38€7 0.0€0.2 16€6 1€1</cell><cell>70€4 53€3 118€2 10€3 6€2 2.0€0.4 40€5 -0.5€0.5 14€6 1€1</cell><cell>77€5 55€2 116€6 4€1 4€2 1.8€0.3 40€4 -0.3€0.5 18€5 1€1</cell><cell>72€2 55€1 111€2 8€4 7€3 1.6€0.3 34€5 0.3€0.2 14€4 1€1</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4</head><label>4</label><figDesc><div><p><s>Effects of psilocybin on blood pressure and body temperature(mean€SEM, n=8)</s></p></div></figDesc><table><row><cell></cell><cell>Placebo</cell><cell>Psilocybin VLD (45 g/kg)</cell><cell>Psilocybin LD (115 g/kg)</cell><cell>Psilocybin MD (215 g/kg)</cell><cell>Psilocybin HD (315 g/kg)</cell></row><row><cell>MAP 1 D MAX MAP 2 AUC (0-t) MAP 3 Body temp (C) AUC (0-t) temp 4</cell><cell>93€3.9 21447€883 -36.5€0.1 8394€31</cell><cell>97€3.9 14€4.4 22199€853 36.6€0.1 8428€16</cell><cell>101€3.6 16€4.7 23069€926 36.4€0.2 8370€36</cell><cell>100€4.2 15€3.9 22935€983 36.5€0.1 8408€21</cell><cell>101€3.9 21€5.3 23158€981 36.6€0.1 8418€28</cell></row></table><note><p><s>(ASAT P&lt;0.001; GGT P&lt;0.002), relative to PL.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5</head><label>5</label><figDesc><div><p><s>Neuroendocrine effects of psilocybin.Dose-dependent plasma concentrations of hormones(mean€SEM, n=8)</s></p></div></figDesc><table><row><cell>Placebo</cell><cell cols="4">Psilocybin VLD (45 g/kg) LD (115 g/kg) MD (215 g/kg) HD (315 g/kg) Psilocybin Psilocybin Psilocybin</cell></row><row><cell>Sampling 1 (baseline, t 020 min )</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Thyroid-stimulating hormone (TSH [mU/l]) Prolactin (PRL [g/l]) Adrenocorticotropic hormone (ACTH [ng/l]) 21€6 1.30€0.15 16.7€5.5 Cortisol (CORT [nmol/l]) 432€59</cell><cell>1.62€0.13 16.0€5.4 17€5 336€54</cell><cell>1.54€0.13 14.6€4.3 17€4 378€77</cell><cell>1.40€0.16 15.5€5.7 18€6 382€50</cell><cell>1.27€0.14 14.8€2.8 12€2 385€71</cell></row><row><cell>Sampling 2 (t 0+105 min )</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Thyroid-stimulating hormone (TSH [mU/l]) Prolactin (PRL [g/l]) Adrenocorticotropic hormone (ACTH [ng/l]) 20€5 1.24€0.16 9.5€2.0 Cortisol (CORT [nmol/l]) 348€50</cell><cell>1.41€0.09 12.8€4.6 19€4 353€85</cell><cell>1.50€0.13 14.5€5.3 25€5 443€47</cell><cell>1.54€0.16 22.4€7.7** 42€14 522€82</cell><cell>1.66€0.22** 28.0€7.5*** 50€12** 567€74*</cell></row><row><cell>Sampling 3 (t 0+300 min )</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Thyroid-stimulating hormone (TSH [mU/l]) Prolactin (PRL [g/l]) Adrenocorticotropic hormone (ACTH [ng/l]) 18€4 1.16€0.15 12.4€2.7 Cortisol (CORT [nmol/l]) 353€54</cell><cell>1.38€0.19 9.0€1.6 15€3 306€64</cell><cell>1.15€0.09 9.1€1.7 15€2 289€60</cell><cell>1.20€0.13 9.7€2.0 14€2 294€57</cell><cell>1.18€0.18 12.9€2.9 15€2 344€61</cell></row><row><cell cols="2">* P&lt;0.05 ** P&lt;0.01 *** P&lt;0.001 compared with placebo condition (Tukey HSD post-hoc test)</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 6</head><label>6</label><figDesc><div><p><s>Plasma concentrations of clinical chemical parameters following administration of four doses of psilocybin(mean€SEM, n=8)</s></p></div></figDesc><table><row><cell>Placebo</cell><cell>Psilocybin VLD (45 g/kg)</cell><cell>Psilocybin LD (115 g/kg)</cell><cell>Psilocybin MD (215 g/kg)</cell><cell>Psilocybin HD (315 g/kg)</cell><cell>Main effect of drug F (4, 28) values</cell><cell>Main effect of drug P values</cell></row><row><cell>Sampling 1 (baseline, t 020 min )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Natrium (Na + [mmol/l]) Potassium (K + [mmol/l]) Chloride (Cl [mmol/l]) Urea (UR [mmol/l]) Creatinine (CR [mol/l]) Lactate dehydrogenase (LDH [U/l]) 272€13 139€2 4.0€0.1 109€3 4.2€0.4 83€6 g-Glutamyltransferase (GGT [U/l]) 13€1 Aspartate aminotransferase 16€2 (ASAT [U/l]) Alanine aminotransferase 13€1 (ALAT [U/l]) Alkaline phosphatase (AP [U/l]) 74€9</cell><cell>140€1 3.9€0.1 104€3 5.1€0.6 87€6 308€18 13€1 18€1 14€2 75€11</cell><cell>141€1 4.0€0.1 100€3 4.6€0.4 82€4 295€20 13€1 17€2 15€2 78€11</cell><cell>139€2 4.0€0.1 102€5 4.6€0.6 82€4 295€21 13€1 18€2 16€3 76€11</cell><cell>140€1 4.0€0.1 108€3 4.3€0.3 83€4 285€13 13€2 16€1 13€1 71€10</cell><cell>0.764 0.891 2.053 2.220 0.732 2.028 1.380 1.548 1.490 0.347</cell><cell>0.558 0.482 0.114 0.093 0.578 0.118 0.266 0.206 0.232 0.844</cell></row><row><cell>Sampling 2 (t 0+105 min )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Natrium (Na + [mmol/l]) Potassium (K + [mmol/l]) Chloride (Cl [mmol/l]) Urea (UR [mmol/l]) Creatinine (CR [mol/l]) Lactate dehydrogenase (LDH [U/l]) 265€18 138€3 3.8€0.1 108€2 4.0€0.4 79€6 g-Glutamyltransferase (GGT [U/l]) 13€2 Aspartate aminotransferase 16€2 (ASAT [U/l]) Alanine aminotransferase 13€2 (ALAT [U/l]) Alkaline phosphatase (AP [U/l]) 74€9</cell><cell>139€1 3.8€0.1 103€2 4.9€0.6 82€4 306€17 13€1 18€2 15€1 76€10</cell><cell>140€1 4.0€0.1 100€1 4.4€0.3 84€5 318€29 13€2 19€2 16€2 78€11</cell><cell>138€3 4.0€0.1 104€3 4.2€0.5 78€5 329€30 14€1 19€2 16€2 83€12</cell><cell>140€1 4.0€0.1 107€2 4.0€0.3 72€3 331€20 16€3** 24€3*** 18€3 80€12</cell><cell></cell><cell></cell></row><row><cell>Sampling 3 (t 0+300 min )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Natrium (Na + [mmol/l]) Potassium (K + [mmol/l]) Chloride (Cl [mmol/l]) Urea (UR [mmol/l]) Creatinine (CR [mol/l]) Lactate dehydrogenase (LDH [U/l]) 271€13 137€3 3.8€0.1 104€3 3.7€0.3 76€6 g-Glutamyltransferase (GGT [U/l]) 12€1 Aspartate aminotransferase (ASAT 16€2 [U/l]) Alanine aminotransferase 13€2 (ALAT [U/l]) Alkaline phosphatase (AP [U/l]) 76€10</cell><cell>140€1 3.8€0.1 104€2 4.6€0.6 80€4 315€11 13€1 19€3 15€2 79€10</cell><cell>140€1 3.9€0.1 101€2 4.0€0.3 82€4 309€16 13€1 19€3 16€2 81€12</cell><cell>138€3 3.9€0.1 103€3 3.9€0.4 78€4 317€21 14€1 18€2 14€2 78€11</cell><cell>141€1 3.8€0.1 109€2 3.7€0.3 78€3 302€13 15€2 20€2 17€2 77€10</cell><cell></cell><cell></cell></row><row><cell cols="3">* P&lt;0.05 ** P&lt;0.01 *** P&lt;0.001 compared with placebo condition (Tukey HSD post-hoc test)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1" xml:id="foot_0"><p><s>Averaged mean arterial pressure (mmHg; 5-210 min post-drug administration)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2" xml:id="foot_1"><p><s>Maximum rise of MAP above averaged placebo values (mmHg)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="3" xml:id="foot_2"><p><s>Area under the MAP-time curve (mmHg min)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="4" xml:id="foot_3"><p><s>Area under the body temperature-time curve(C min)</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><p>Acknowledgements The authors thank <rs type="person">Drs Dieter Vonderschmitt</rs>, <rs type="person">Arnold von Eckardstein</rs>, and <rs type="person">Kathrin Rentsch</rs>, <rs type="affiliation">Institute of Clinical Chemistry of the University of Zürich</rs>, for analysis of hormones and clinical-chemical parameters, and <rs type="person">Martin Dobricki</rs> for assistance during the experimental part of the study.The authors especially thank <rs type="person">Drs Stephan Ludewig</rs>, <rs type="person">David Nichols</rs>, <rs type="person">George Greer</rs>, and <rs type="person">Francisco Moreno</rs> for critical comments on the manuscript.This investigation was financially supported by the <rs type="funder">Heffter Research Institute</rs>, <rs type="person">Santa Fe</rs>, <rs type="institution">New Mexico, USA</rs>, and the <rs type="funder">Swiss Federal Office for Public Health (BAG</rs> grant no.<rs type="grantNumber">00.001023</rs>).</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_TTQRfez">
					<idno type="grant-number">00.001023</idno>
				</org>
			</listOrg>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Serotonin and hallucinogens</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Aghajanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="16S" to="23" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Multicentre evaluation of the Boehringer Mannheim/Hitachi 747 analysis system</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bonini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ceriotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Brauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Stolz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pascual</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Garcia-Beltran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Vonderschmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Chem Clin Biochem</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="881" to="899" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Role of serotonin in memory impairment</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Buhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Segu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Med</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="210" to="221" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states</title>
		<author>
			<persName><forename type="first">I</forename><surname>Creese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Burt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Snyder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Life Sci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1715" to="1719" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Increasing use of &apos;ecstasy&apos; (MDMA) and other hallucinogens on a college campus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Cuomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Dyment</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Gammino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am College Health</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="271" to="274" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">SCL-90: an outpatient psychiatric rating scale-preliminary report</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Derogatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Lipman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Covi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharm Bull</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="13" to="28" />
			<date type="published" when="1973">1973</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Psychological aspects of altered states of consciousness of the LSD type: measurement of their basic dimensions and prediction of individual differences</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dittrich</surname></persName>
		</author>
		<editor>Pletscher A, Ladewig D</editor>
		<imprint>
			<date type="published" when="1993">1993</date>
			<publisher>Parthenon</publisher>
			<biblScope unit="page" from="101" to="118" />
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note>Fifty years of LSD. Current status and perspectives of hallucinogens</note>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">¾tiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dittrich</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1996">1996</date>
			<publisher>VWB Verlag</publisher>
			<pubPlace>Berlin</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The standardized psychometric assessment of altered states of consciousness (ASCs) in humans</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dittrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacopsychology</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="80" to="84" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<author>
			<persName><forename type="first">A</forename><surname>Dittrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lamparter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">D-ABZ: Fragebogen zur Erfassung Aussergewöhnlicher Bewusstseinszustände</title>
		<meeting><address><addrLine>Zürich</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1999">1999</date>
			<biblScope unit="volume">5</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Thyroid axis activity and serotonin function in major depressive episode</title>
		<author>
			<persName><forename type="first">F</forename><surname>Duval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Mokrani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Correa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Diep</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Crocq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Macher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychoneuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="695" to="712" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The pharmacology of human working memory</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Nathan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="299" to="313" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Das Freiburger Persönlichkeitsinventar FPI</title>
		<author>
			<persName><forename type="first">J</forename><surname>Fahrenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hampel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Selg</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1984">1984</date>
			<pubPlace>Göttingen, Hogrefe</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<author>
			<persName><forename type="first">R</forename><surname>Fried</surname></persName>
		</author>
		<title level="m">Aspartatamino-transferase (AST, ASAT, GOT) im Plasma</title>
		<imprint>
			<date type="published" when="2000">2000</date>
		</imprint>
		<respStmt>
			<orgName>Manual of the Institute of Clinical Chemistry of the University Hospital of Zürich. Zürich</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Serotonergic stimulation of pituitary-adrenocortical function in rats</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Fuller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="118" to="127" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gouzoulis-Mayfrank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Heekeren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Thelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lindenblatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Kovar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Geyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav Pharmacol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="561" to="566" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Psychopathological, neuroendocrine and autonomic effects of 3,4-methlyenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gouzoulis-Mayfrank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Thelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Habermeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Kunert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Kovar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lindenblatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hermle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Spitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sass</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="41" to="50" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">Untersuchungen zur Humanpharmakokinetik von Psilocybin. Thesis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Hasler</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1997">1997</date>
		</imprint>
		<respStmt>
			<orgName>University of Bern</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man</title>
		<author>
			<persName><forename type="first">F</forename><surname>Hasler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bourquin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brenneisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Baer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharm Acta Helv</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="175" to="184" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Clinical, biochemical and psychologic effects of psilocybin</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Hollister</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Int Pharmacodyn Ther</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="42" to="53" />
			<date type="published" when="1961">1961</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Role of serotonin in the control of secretion of corticotropin releasing factor</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Direnzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Beckford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gillham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Endocrinol</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="151" to="160" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Comparison of reactions induced by psilocybin and LSD-25 in man</title>
		<author>
			<persName><forename type="first">H</forename><surname>Isbell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="29" to="38" />
			<date type="published" when="1959">1959</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main">Die Eigenschaftswörterliste (EWL-K)-Ein Verfahren zur Erfassung der Befindlichkeit</title>
		<author>
			<persName><forename type="first">W</forename><surname>Janke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Debus</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1978">1978</date>
			<pubPlace>Hogrefe, Göttingen</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Serotonin-dopamine interaction and its relevance to schizophrenia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kapur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Remington</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="466" to="476" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Analytical performance of the random access analyser Hitachi 737. A multicentre evaluation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Knedel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Haeckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Seidel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thiery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Vonderschmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Haenseler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Chem Clin Biochem</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="409" to="432" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Neurotransmitter control of thyrotropin secretion</title>
		<author>
			<persName><forename type="first">L</forename><surname>Krulich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="139" to="147" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<author>
			<persName><forename type="first">L</forename><surname>Laux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Glanzmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schaffner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Spielberger</surname></persName>
		</author>
		<title level="m">Das State-Trait-Angstinventar (STAI)</title>
		<meeting><address><addrLine>Beltz, Weinheim</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lindenblatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kraemer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Holzmann-Erens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gouzoulis-Mayfrank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Kovar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Chromatogr B</title>
		<imprint>
			<biblScope unit="volume">709</biblScope>
			<biblScope unit="page" from="255" to="263" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Biological drugs-is there a change in substance abuse?</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lohrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Albers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatr Prax</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="199" to="201" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Central regulation of thyrotropin secretion in rats: methodological aspects, problems and some progress</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Mannisto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Biol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="92" to="100" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Marek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Aghajanian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Alcohol Depend</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="189" to="198" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Repke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Peroutka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="193" to="198" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Serotonin and mood: neuroendocrine aspects</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Meltzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Nash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Neuroendocrinology of mood</title>
		<editor>
			<persName><forename type="first">D</forename><surname>Ganten</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">D</forename><surname>Pfaff</surname></persName>
		</editor>
		<meeting><address><addrLine>Berlin Heidelberg New York</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="1988">1988</date>
			<biblScope unit="page" from="183" to="210" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory</title>
		<author>
			<persName><forename type="first">A</forename><surname>Meneses</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Neurosci</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="275" to="289" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Effects of serotonergic system on hypothalamic-pituitary-thyroid axis in rats</title>
		<author>
			<persName><forename type="first">T</forename><surname>Mitsuma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nogimori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Horm Metab Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="346" to="349" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">The role of serotonin (5-HT) in the control of TSH and prolactin release in euthyroid subjects assessed by the administration of ketanserin (5-HT2 antagonist) and zimelidine (5-HT re-uptake inhibitor)</title>
		<author>
			<persName><forename type="first">H</forename><surname>Moosbrugger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J ;</forename><surname>Oehlschlägel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hans</forename><surname>Testmanual</surname></persName>
		</author>
		<author>
			<persName><surname>Huber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Göttingen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Malley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Jennings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Barnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Rosenthal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychoneuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="13" to="19" />
			<date type="published" when="1984">1996. 1984</date>
		</imprint>
	</monogr>
	<note>FAIR Frankfurter Aufmerksamkeitsinventar</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The pharmacology of psilocybin</title>
		<author>
			<persName><forename type="first">T</forename><surname>Passie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Seifert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Emrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Addict Biol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="357" to="364" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">The effect of ketanserin, a specific serotonin antagonist on the PRL, HG, ACTH and cortisol response to hypoglycaemia in normal subjects</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Prescott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kendall-Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Weightman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Ratcliffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Endocrinol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="137" to="142" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Central cardiovascular regulation and 5hydroxytryptamine receptors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Ramage</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res Bull</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="425" to="439" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Prolactinomas in women: current therapies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Nelson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Int Med</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="115" to="118" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Ego-psychopathology: the concept and its empirical evaluation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Scharfetter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychol Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="273" to="280" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Facilitatory role of serotonin (5-HT) in the control of thyrotropin releasing hormone/throtropin (TRH/ TSH) secretion in rats</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Nunes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Braz J Med Biol Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="677" to="683" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Dose-response study of N,Ndimethyltryptamine in humans. I. Neuroendocrine, autonomic and cardiovascular effects</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Strassman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Qualls</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="85" to="97" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Psychoactive mushrooms-an update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Supprian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Supprian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rosler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wanke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Fortschr Neurol Psychiatr</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="597" to="602" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Van De Kar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Karteszi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Bethea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Ganong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="380" to="384" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Van De Kar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Javed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Serres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Raap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Thackery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="3572" to="3579" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">A systems model of altered consciousness: integrating natural and drug-induced psychoses</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Geyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res Bull</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="495" to="507" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Leenders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Scharfetter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Maguire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Stadelmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Angst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="357" to="372" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Psilocybin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Vollenweider-Scherpenhuyzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Babler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="3897" to="3902" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">5-HT modulation of dopamine release in basal ganglia in psilocybininduced psychosis in man-a PET study with ( 11 C)raclopride</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Vollenweider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vontobel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Leenders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="424" to="433" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">The physiological role of 5-HT 2A receptors in working memory</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Goldman-Rakic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="2843" to="2854" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">DIA-X-Interview</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Wittchen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pfister</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="s">Swet Test Services</title>
		<imprint>
			<date type="published" when="1997">1997</date>
			<pubPlace>Frankfurt</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
